BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-07
185 industry Phase 2/3 trial readout(s) and 29 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2024-07-01 | Complete response letter | complete response | Amneal EU, Ltd. AMRX | CRL 2024-07-01: Amneal EU, Ltd. NDA 218345 | |
| 2024-07-01 | FDA approval | approved | VIFOR FRESENIUS | VELPHORO | Approved 2024-07-01: VELPHORO (NDA205109 SUPPL9) |
| 2024-07-02 | FDA approval | approved | ELI LILLY CO LLY | KISUNLA | Approved 2024-07-02: KISUNLA (BLA761248 ORIG1) |
| 2024-07-04 | Complete response letter | approved since | Samsung Bioepis Co., Ltd. | Pyzchiva (ustekinumab-ttwe) injection | CRL 2024-07-04: Samsung Bioepis Co., Ltd. BLA 761373/Original 2, BLA 761425/Original 2, BLA 761373, BLA 761425 (Pyzchiva (ustekinumab-ttwe) injection) |
| 2024-07-05 | FDA approval | approved | MERZ PHARMS | Xeomin | Approved 2024-07-05: Xeomin (BLA125360 SUPPL99) |
| 2024-07-09 | FDA approval | approved | ARCUTIS ARQT | ZORYVE | Approved 2024-07-09: ZORYVE (NDA215985 SUPPL7) |
| 2024-07-10 | Complete response letter | complete response | Novo Nordisk Inc. NVO | NNC0148-0287 injection | CRL 2024-07-10: Novo Nordisk Inc. BLA 761326 (NNC0148-0287 injection) |
| 2024-07-11 | Complete response letter | complete response | MEDRx USA, Inc. | CRL 2024-07-11: MEDRx USA, Inc. NDA 215029 | |
| 2024-07-11 | FDA approval | approved | LONG GROVE PHARMS | VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Approved 2024-07-11: VASOPRESSIN IN SODIUM CHLORIDE 0.9% (NDA217766 ORIG1) |
| 2024-07-13 | FDA approval | approved | WSM SUPPLIER LLC | MEDICAL AIR USP | Approved 2024-07-13: MEDICAL AIR, USP (NDA219709 ORIG1) |
| 2024-07-15 | Complete response letter | complete response | Orexo AB | Naloxone hydrochloride nasal powder, °® | CRL 2024-07-15: Orexo AB NDA 217433 (Naloxone hydrochloride nasal powder, °®) |
| 2024-07-17 | FDA approval | approved | PHATHOM PHARMACEUTICALS INC PHAT | VOQUEZNA | Approved 2024-07-17: VOQUEZNA (NDA218710 ORIG1) |
| 2024-07-18 | FDA approval | approved | ZYDUS LIFESCIENCES | ZITUVIMET XR | Approved 2024-07-18: ZITUVIMET XR (NDA216778 ORIG1) |
| 2024-07-19 | FDA approval | approved | SAMSUNG BIOEPIS CO LTD | EPYSQLI | Approved 2024-07-19: EPYSQLI (BLA761340 ORIG1) |
| 2024-07-22 | FDA approval | approved | MILLICENT MFG PR | FEMLYV | Approved 2024-07-22: FEMLYV (NDA218718 ORIG1) |
| 2024-07-22 | FDA approval | approved | XIAMEN LP PHARM CO | OPIPZA | Approved 2024-07-22: OPIPZA (NDA216655 ORIG1) |
| 2024-07-22 | FDA approval | approved | NOVARTIS NVS | KISQALI | Approved 2024-07-22: KISQALI (NDA209092 SUPPL19) |
| 2024-07-24 | FDA approval | approved | MIRUM MIRM | LIVMARLI | Approved 2024-07-24: LIVMARLI (NDA214662 SUPPL10) |
| 2024-07-24 | FDA approval | approved | BIOMARIN PHARM BMRN | BRINEURA | Approved 2024-07-24: BRINEURA (BLA761052 SUPPL14) |
| 2024-07-25 | FDA AdCom | held | AstraZeneca UK Limited AZN | AdCom 2024-07-25: Oncologic Drugs Advisory Committee - sBLA 761069/S-043 | |
| 2024-07-25 | Complete response letter | complete response | Xspray Pharma AB | “” (dasatinib) tablets | CRL 2024-07-25: Xspray Pharma AB NDA 216195 (“” (dasatinib) tablets) |
| 2024-07-25 | FDA approval | approved | SUN PHARM INDS INC | LEQSELVI | Approved 2024-07-25: LEQSELVI (NDA217900 ORIG1) |
| 2024-07-26 | Complete response letter | complete response | RB Health (US) LLC | naproxen sodium |), dextromethorphan hydrobromide (4, guaifenesin | @) extended-release (ER) tablet | CRL 2024-07-26: RB Health (US) LLC NDA 217338 (naproxen sodium |), dextromethorphan hydrobromide (4, guaifenesin | @) extended-release (ER) tablet) |
| 2024-07-26 | FDA approval | approved | AMNEAL AMRX | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | Approved 2024-07-26: POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE (NDA218343 ORIG1) |
| 2024-07-26 | FDA approval | approved | LUYE INNOMIND PHARMA | ERZOFRI | Approved 2024-07-26: ERZOFRI (NDA216352 ORIG1) |
| 2024-07-26 | FDA approval | approved | ALPHA COGNITION ACOG | ZUNVEYL | Approved 2024-07-26: ZUNVEYL (NDA218549 ORIG1) |
| 2024-07-29 | FDA approval | approved | NOVITIUM PHARMA | TEZRULY | Approved 2024-07-29: TEZRULY (NDA218139 ORIG1) |
| 2024-07-30 | FDA approval | approved | JANSSEN BIOTECH | DARZALEX FASPRO | Approved 2024-07-30: DARZALEX FASPRO (BLA761145 SUPPL25) |
| 2024-07-31 | FDA approval | approved | JANSSEN BIOTECH | DARZALEX | Approved 2024-07-31: DARZALEX (BLA761036 SUPPL50) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-07 est. | P2 | Emerald Health Pharmaceuticals | NCT04166552 Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis | Diffuse Cutaneous Systemic Sclerosis | suspended | 36 |
| 2024-07 est. | P3 | Everstar Therapeutics Limited | NCT04176588 A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis | Moderately to Severely Active Ulcerative Colitis | unknown | 341 |
| 2024-07 est. | P1/P2 | Mural Oncology, Inc | NCT04592653 Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) | Advanced Solid Tumor | active not recruiting | 78 |
| 2024-07 est. | P2 | Sorrento Therapeutics, Inc. | NCT04992247 Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise | Covid19 | withdrawn | |
| 2024-07 est. | P1/P2 | iTeos Belgium SA | NCT05060432 Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors | Advanced Cancer; Lung Cancer; Head and Neck Cancer; Melanoma | unknown | 153 |
| 2024-07 est. | P3 | EMS | NCT05144360 Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension | Hypertension Associated; Type II Diabetes Mellitus | withdrawn | |
| 2024-07 est. | P3 | Inmunotek S.L. | NCT05400811 Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis | House Dust Mite Allergy; Perennial Allergic Rhinitis; Allergic Rhinoconjunctivitis; Allergic Asthma | unknown | 400 |
| 2024-07 est. | P2 | Shanghai Ark Biopharmaceutical Co., Ltd. | NCT05424887 A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | unknown | 105 |
| 2024-07 est. | P1/P2 | Shanghai EpimAb Biotherapeutics Co., Ltd. | NCT05498389 EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Stage IV Lung Canc | unknown | 115 |
| 2024-07 est. | P1/P2 | Shanghai AbelZeta Ltd. | NCT05521802 A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | recruiting | 92 |
| 2024-07 est. | P3 | Boryung Biopharma Co., Ltd. | NCT05613127 To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs | Hepatitis A; Hep A | unknown | 106 |
| 2024-07 est. | P2 | Shanghai JMT-Bio Inc. | NCT06089330 A Study of JMT101 in Patients With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer (mCRC) | unknown | 102 |
| 2024-07 est. | P2 | Vanda Pharmaceuticals VNDA | NCT06296966 A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye | Dry Eye | unknown | 40 |
| 2024-07-01 | P1/P2 | Teva Branded Pharmaceutical Products R&D LLC | NCT03215030 A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | terminated | 272 |
| 2024-07-01 | P3 | Prestige Biopharma Limited PBH | NCT03390686 A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients | Lung Cancer; Non-small Cell Lung Cancer | active not recruiting | 650 |
| 2024-07-01 est. | P3 | Lupin Ltd. | NCT04700046 Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2 | Myotonic Dystrophy Type 1 and Type 2 | withdrawn | |
| 2024-07-01 | P2 | Actinogen Medical | NCT05657691 Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD) | Major Depressive Disorder; MDD; Cognitive Impairment | completed | 167 |
| 2024-07-01 | P3 | Eli Lilly and Company LLY | NCT05691712 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes | Diabetes Type 2; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Disease; Endocrine Syste | completed | 257 |
| 2024-07-01 est. | P2/P3 | KARE Biosciences | NCT05706454 Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia | COVID-19 Pneumonia; COVID-19 Respiratory Infection | unknown | 324 |
| 2024-07-01 | P2 | Immuron Ltd. IMRN | NCT05933525 Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model. | Diarrhea; Travelers Diarrhea; Infectious Diarrhea | completed | 63 |
| 2024-07-02 | P2 | Novartis Pharmaceuticals NVS | NCT04573920 Atrasentan in Patients With Proteinuric Glomerular Diseases | IgA Nephropathy; Focal Segmental Glomerulosclerosis; Alport Syndrome; Diabetic Kidney Disease; Diabe | active not recruiting | 103 |
| 2024-07-02 | P3 | Eli Lilly and Company LLY | NCT04847557 A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Obesity; Heart Failure With Preserved Ejection Fraction (HFpEF) | completed | 731 |
| 2024-07-02 | P3 | Celgene | NCT05214768 A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis | Eosinophilic Gastroenteritis | completed | 48 |
| 2024-07-02 | P2 | Novartis Pharmaceuticals NVS | NCT05562934 An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. | Resistant Hypertension | completed | 189 |
| 2024-07-02 | P1/P2 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | NCT05682170 Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML) | terminated | 40 |
| 2024-07-02 | P2 | Gilead Sciences GILD | NCT05729568 A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection | HIV-1 Infection | active not recruiting | 83 |
| 2024-07-02 | P1/P2 | GlaxoSmithKline | NCT05823974 A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults | Influenza, Human | completed | 1275 |
| 2024-07-03 | P2 | Takeda TAK | NCT02924272 Ixazomib Rollover Study | Multiple Myeloma; Lymphoma; Amyloidosis | completed | 32 |
| 2024-07-03 | P3 | LEO Pharma | NCT03587805 Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND | Atopic Dermatitis | completed | 1672 |
| 2024-07-03 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT03825744 Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia | Severe Aplastic Anemia | completed | 240 |
| 2024-07-03 | P3 | Agios Pharmaceuticals, Inc. AGIO | NCT03853798 Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007 | Pyruvate Kinase Deficiency | completed | 90 |
| 2024-07-03 | P2 | Revolution Medicines, Inc. RVMD | NCT05054725 Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Non-Small Cell Lung Cancer | completed | 47 |
| 2024-07-03 | P3 | Hangzhou Sciwind Biosciences Co., Ltd. | NCT05680129 A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM | T2DM; Type 2 Diabetes Mellitus | completed | 623 |
| 2024-07-03 | P2 | Invirsa, Inc. | NCT06370039 Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease | Dry Eye Disease | completed | 109 |
| 2024-07-04 | P2 | MacroGenics MGNX | NCT05551117 A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors | Castration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Insensitive P | terminated | 192 |
| 2024-07-04 | P2 | Topas Therapeutics GmbH | NCT05660109 A Study to Assess the Safety of TPM502 in Adults With Celiac Disease | Celiac Disease | completed | 28 |
| 2024-07-04 | P1/P2 | Keymed Biosciences Co.Ltd | NCT06162507 Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis | Atopic Dermatitis | completed | 24 |
| 2024-07-05 | P1/P2 | Cytovation AS | NCT04260529 CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations | Advanced Solid Tumor Malignancy | completed | 60 |
| 2024-07-05 | P2 | Alexion Pharmaceuticals, Inc. | NCT05019521 A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | Geographic Atrophy | terminated | 365 |
| 2024-07-05 | P2 | AbbVie ABBV | NCT05141006 Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome | Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | completed | 83 |
| 2024-07-05 est. | P2 | Takeda TAK | NCT05469802 A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults | Healthy Volunteers | withdrawn | |
| 2024-07-05 | P3 | AMIpharm Co., Ltd. | NCT06256445 Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area | Healthy | completed | 252 |
| 2024-07-05 | P3 | SPH-BIOCAD (HK) Limited | NCT07277179 Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondyl | Ankylosing Spondylitis | completed | 113 |
| 2024-07-08 | P3 | AstraZeneca AZN | NCT04269200 Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer | Endometrial Neoplasms | active not recruiting | 805 |
| 2024-07-08 | P1/P2 | PT. Prodia Stem Cell Indonesia | NCT04314661 Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis | Osteoarthritis, Knee | completed | 31 |
| 2024-07-08 | P3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT04687241 Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations | Non-small Cell Lung Cancer | active not recruiting | 192 |
| 2024-07-08 | P2 | Boehringer Ingelheim | NCT04978493 A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease | Crohn Disease | terminated | 49 |
| 2024-07-08 | P2 | Day One Biopharmaceuticals, Inc. | NCT04985604 Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Melanoma; Solid Tumor; CRAF Gene Amplification; RAF1 Gene Amplification; BRAF Gene Fusion; BRAF Fusi | terminated | 23 |
| 2024-07-08 | P2 | Treos Bio Limited | NCT05243862 Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | Colorectal Cancer Metastatic | completed | 18 |
| 2024-07-08 | P3 | Aridis Pharmaceuticals, Inc. | NCT05331885 A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2 | Ventilator Associated Pneumonia; Staphylococcus Aureus | terminated | 24 |
| 2024-07-08 est. | P2 | GlaxoSmithKline | NCT05340257 A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS | Infections, Bacterial | withdrawn | |
| 2024-07-08 | P3 | Ipsen | NCT05458856 Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate | Prostate Cancer | completed | 147 |
| 2024-07-09 | P1/P2 | Baxalta now part of Shire | NCT03370172 A Study of BAX 888 in Male Adults With Severe Hemophilia A | Hemophilia A | completed | 4 |
| 2024-07-09 | P2 | Navidea Biopharmaceuticals | NCT04078191 Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA | Rheumatoid Arthritis | terminated | 20 |
| 2024-07-09 | P2/P3 | Merck Sharp & Dohme LLC MRK | NCT04767373 Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) | Respiratory Syncytial Virus Infection | completed | 3632 |
| 2024-07-09 | P2 | Alpine Immune Sciences Inc, A Subsidiary of Vertex | NCT04835441 ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | completed | 76 |
| 2024-07-09 | P1/P2 | Inozyme Pharma | NCT05030831 Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE | ATP-Binding Cassette Subfamily C Member 6 Deficiency; Pseudoxanthoma Elasticum; Generalized Arterial | completed | 10 |
| 2024-07-09 | P2 | Eli Lilly and Company LLY | NCT05063539 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease | Alzheimer Disease | completed | 327 |
| 2024-07-09 | P3 | Navidea Biopharmaceuticals | NCT05246280 Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA | Rheumatoid Arthritis | terminated | 169 |
| 2024-07-09 | P2 | Jiangsu vcare pharmaceutical technology co., LTD | NCT05997927 Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis | Moderate to Severe Atopic Dermatitis | completed | 149 |
| 2024-07-10 | P3 | Kolon TissueGene, Inc. | NCT03203330 A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee | Degenerative Osteoarthritis | active not recruiting | 535 |
| 2024-07-10 | P3 | Onconic Therapeutics Inc. | NCT05448001 Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer | Gastric Ulcer | completed | 329 |
| 2024-07-10 | P2 | Neurocrine Biosciences NBIX | NCT05545111 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia | Schizophrenia | completed | 210 |
| 2024-07-11 | P1/P2 | Sangamo Therapeutics SGMOQ | NCT04817774 Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients | Kidney Transplant Rejection; End Stage Renal Disease | completed | 26 |
| 2024-07-11 est. | P1/P2 | Algenis SpA | NCT05052398 Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral Neuropathy | Chemotherapy-induced Peripheral Neuropathy | unknown | 52 |
| 2024-07-11 | P2 | Rakuten Medical, Inc. | NCT05182866 ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer | Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck | unknown | 9 |
| 2024-07-11 | P3 | Celltrion | NCT05385770 Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects | Essential Hypertension | completed | 890 |
| 2024-07-11 | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT05870319 A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients | Non-small Cell Lung Cancer | active not recruiting | 376 |
| 2024-07-12 | P1/P2 | Fore Biotherapeutics | NCT02428712 A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | Advanced Unresectable Solid Tumors; BRAF-mutated Tumors | completed | 113 |
| 2024-07-12 | P2 | Vivoryon Therapeutics N.V. | NCT03919162 A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD | Alzheimer Disease | terminated | 112 |
| 2024-07-12 | P2 | Janssen Research & Development, LLC | NCT04172675 A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With Hig | Urinary Bladder Neoplasms | completed | 107 |
| 2024-07-12 | P2/P3 | Regeneron Pharmaceuticals REGN | NCT04206553 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | Bullous Pemphigoid | completed | 106 |
| 2024-07-12 | P3 | GlaxoSmithKline | NCT05281523 Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) | Nasal Polyps | completed | 264 |
| 2024-07-12 | P3 | Vanda Pharmaceuticals VNDA | NCT05366855 Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP | Generalized Pustular Psoriasis | terminated | 42 |
| 2024-07-12 | P3 | Merck Sharp & Dohme LLC MRK | NCT05722015 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastati | Metastatic Non-small Cell Lung Cancer | active not recruiting | 377 |
| 2024-07-12 | P3 | CanSino Biologics Inc. | NCT06131554 A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years | Meningococcal Meningitis | completed | 1480 |
| 2024-07-12 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT06490484 Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin | Diabetic Peripheral Neuropathic Pain | unknown | 90 |
| 2024-07-13 | P2 | Arvinas Inc. ARVN | NCT05549505 A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | Breast Cancer | completed | 152 |
| 2024-07-13 | P2 | Gan and Lee Pharmaceuticals, USA | NCT06202079 A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | completed | 179 |
| 2024-07-13 | P2 | Vincentage Pharma Co., Ltd | NCT06569355 A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population | Obesity; Overweight | completed | 250 |
| 2024-07-15 | P3 | Sanofi SNY | NCT04410978 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) | Relapsing Multiple Sclerosis | completed | 974 |
| 2024-07-15 | P2/P3 | LeonaBio LONA | NCT04488419 ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease | Alzheimer Disease; Dementia of Alzheimer Type | completed | 554 |
| 2024-07-15 | P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT04539938 A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer | HER2 Positive Breast Cancer | completed | 70 |
| 2024-07-15 est. | P3 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT04951635 A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | recruiting | 150 |
| 2024-07-15 | P3 | Viridian Therapeutics, Inc. VRDN | NCT05176639 A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) | Thyroid Eye Disease | completed | 113 |
| 2024-07-15 | P3 | Orca Biosystems, Inc. | NCT05316701 Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Mixed Phenotype Acute Leukemia; Undifferentiated Le | active not recruiting | 187 |
| 2024-07-15 | P2 | Forma Therapeutics, Inc. | NCT05568225 A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) | Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R | terminated | 17 |
| 2024-07-15 | P2 | Technovalia, Pty Ltd | NCT05605470 Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults | COVID-19, SARS CoV 2 Infection | completed | 150 |
| 2024-07-15 est. | P3 | Johnson & Johnson Consumer Inc. (J&JCI) JNJ | NCT05845008 A Multiple-Dose Safety Study of Fixed Combination of Acetaminophen/Naproxen Sodium in Adolescents With Orthodontic Pain | Orthodontic Pain | withdrawn | |
| 2024-07-15 | P2 | Incyte Corporation INCY | NCT05906628 Topical Ruxolitinib Evaluation in Chronic Hand Eczema | Hand Eczema | completed | 186 |
| 2024-07-15 | P2 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | NCT06680466 A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery | Pain | completed | 179 |
| 2024-07-15 | P1/P2 | MindRank AI Ltd | NCT06778850 A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants | Overweight and Obese Volunteers | completed | 128 |
| 2024-07-16 | P2 | Pfizer PFE | NCT03061201 A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A | Hemophilia A | completed | 13 |
| 2024-07-16 | P3 | Sanofi SNY | NCT04410991 Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) | Relapsing Multiple Sclerosis | completed | 899 |
| 2024-07-16 | P2 | Santhera Pharmaceuticals | NCT05185622 A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | completed | 54 |
| 2024-07-16 | P1/P2 | ModernaTX, Inc. | NCT05972174 A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults | Influenza | completed | 1504 |
| 2024-07-17 | P1/P2 | Incyte Corporation INCY | NCT05222555 Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients | Diffuse Large B Cell Lymphoma | active not recruiting | 53 |
| 2024-07-17 | P2 | Escient Pharmaceuticals, Inc | NCT05525520 Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis | Pruritus | completed | 62 |
| 2024-07-17 | P2 | Annexin Pharmaceuticals AB | NCT05532735 Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion | Retinal Vein Occlusion | completed | 16 |
| 2024-07-17 | P2 | Armata Pharmaceuticals, Inc. ARMP | NCT05616221 Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomo | Non-cystic Fibrosis Bronchiectasis; Pseudomonas Aeruginosa; Lung Infection | completed | 48 |
| 2024-07-17 | P1/P2 | Vaxcyte, Inc. PCVX | NCT06151288 Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults | Pneumococcal Vaccines | completed | 1015 |
| 2024-07-17 | P2 | Icosavax, Inc. | NCT06481579 A Study of IVX-A12 in Adults Participants | Healthy Participants | completed | 143 |
| 2024-07-18 | P1/P2 | PDC*line Pharma SAS | NCT03970746 Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | Non Small Cell Lung Cancer | active not recruiting | 73 |
| 2024-07-18 | P3 | Sun Pharmaceutical Industries, Inc. | NCT05041803 European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | Alopecia Areata | completed | 407 |
| 2024-07-18 | P3 | Enzene Biosciences Ltd. | NCT05405725 A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® | Postmenopausal Osteoporosis | completed | 504 |
| 2024-07-18 | P2 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NCT05551598 Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) | Neuromyelitis Optica Spectrum Disorder | completed | 46 |
| 2024-07-18 | P2 | Keymed Biosciences Co.Ltd | NCT05715320 Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | completed | 160 |
| 2024-07-18 | P2 | Huahui Health | NCT05861674 A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection | Chronic Hepatitis Delta Virus Infection | completed | 101 |
| 2024-07-18 | P3 | Novo Nordisk A/S NVO | NCT05878938 A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) | Haemophilia A; Haemophilia A With Inhibitors | completed | 61 |
| 2024-07-19 | P2 | Hoffmann-La Roche | NCT04225715 A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B | Hepatitis B, Chronic | completed | 281 |
| 2024-07-19 | P3 | Eli Lilly and Company LLY | NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) | Atopic Dermatitis | completed | 1153 |
| 2024-07-19 | P1/P2 | Akeso | NCT05505825 A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer | SCLC,Extensive Stage | completed | 36 |
| 2024-07-19 | P3 | Eli Lilly and Company LLY | NCT05662332 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time ( | Type 2 Diabetes; T2D | completed | 795 |
| 2024-07-19 | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05970978 A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics | Psoriasis | completed | 152 |
| 2024-07-19 | P2 | Suven Life Sciences Limited | NCT06126497 Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients | Major Depressive Disorder | completed | 41 |
| 2024-07-19 | P1/P2 | Iovate Health Sciences International Inc | NCT06628596 Acute Effects of Paraxanthine on Energy and Focus | Cognition; Appetite; Mental Energy; Dietary Supplement | completed | 25 |
| 2024-07-20 | P1/P2 | Bayer | NCT02637687 A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Solid Tumors Harboring NTRK Fusion | active not recruiting | 154 |
| 2024-07-20 | P3 | Ignis Therapeutics (Suzhou) Limited | NCT06103825 A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatm | Sleep Apnea, Obstructive; Excessive Daytime Sleepiness | completed | 204 |
| 2024-07-20 est. | P2 | Gan and Lee Pharmaceuticals, USA | NCT06256549 A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus | Type 2 Diabetes | unknown | 272 |
| 2024-07-21 | P3 | Otsuka Beijing Research Institute | NCT05650320 To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD | Atopic Dermatitis (AD) | completed | 240 |
| 2024-07-22 | P3 | Biogen BIIB | NCT04241068 A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221 | Alzheimer's Disease | terminated | 1696 |
| 2024-07-22 | P2/P3 | Edesa Biotech Inc. EDSA | NCT04401475 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COV | COVID-19; ARDS | terminated | 278 |
| 2024-07-22 | P2/P3 | Regeneron Pharmaceuticals REGN | NCT04695977 CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | Melanoma; Advanced Melanoma; Metastatic Melanoma; Unresectable Melanoma | terminated | 20 |
| 2024-07-22 | P2 | Amgen AMGN | NCT05032066 A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | terminated | 153 |
| 2024-07-22 | P3 | AstraZeneca AZN | NCT05755932 Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants | Mucociliary Clearance | completed | 35 |
| 2024-07-22 | P1/P2 | Beijing QL Biopharmaceutical Co.,Ltd | NCT07065032 A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes | completed | 27 |
| 2024-07-23 | P3 | GenSight Biologics | NCT03293524 Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year | Leber Hereditary Optic Neuropathy | completed | 98 |
| 2024-07-23 | P2 | ImmuneOncia Therapeutics Inc. | NCT04414163 A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | Extranodal NK/T-cell Lymphoma, Nasal Type; Extranodal NK/T-cell Lymphoma | active not recruiting | 23 |
| 2024-07-23 | P3 | Haisco-USA Pharmaceuticals, Inc. | NCT05486416 Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery | General Anesthesia | completed | 465 |
| 2024-07-23 | P2 | Amylyx Pharmaceuticals Inc. AMLX | NCT05676034 AMX0035 in Adult Patients With Wolfram Syndrome | Wolfram Syndrome | active not recruiting | 12 |
| 2024-07-23 | P2 | LifeSeasons Inc. | NCT06672094 A Study to Investigate the Safety and Efficacy of NeuroQ on Cognitive Function in Health Adults with Self-Reported Memory Problems | Healthy; Self-reported Memory Problems | completed | 40 |
| 2024-07-24 | P1/P2 | Vaccinex Inc. VCNX | NCT04815720 Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | completed | 49 |
| 2024-07-24 | P3 | AstraZeneca AZN | NCT05104866 A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive | Breast Cancer | active not recruiting | 732 |
| 2024-07-24 | P2 | Fujian Akeylink Biotechnology Co., Ltd. | NCT05637541 Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets | Chronic Hepatitis b | completed | 90 |
| 2024-07-24 | P3 | ACELYRIN Inc. | NCT05905783 Hidradenitis Suppurativa Study of Izokibep | Hidradenitis Suppurativa | terminated | 258 |
| 2024-07-24 | P2 | Thirty Respiratory Limited | NCT06041919 Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis | Rifampicin Susceptible Pulmonary Tuberculosis | terminated | 20 |
| 2024-07-25 | P1/P2 | Imunon IMNN | NCT03393884 Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | active not recruiting | 130 |
| 2024-07-25 | P3 | Merck Sharp & Dohme LLC MRK | NCT03765918 Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-347 | Head and Neck Neoplasms | active not recruiting | 714 |
| 2024-07-25 | P3 | Intra-Cellular Therapies, Inc. | NCT04959032 Lumateperone for the Prevention of Relapse in Patients With Schizophrenia | Schizophrenia | completed | 592 |
| 2024-07-25 est. | P2 | Scarless Laboratories, Inc. | NCT05501327 Dose Regimen Study of SLI-F06 in Healthy Volunteers | Scar; Wound Healing | recruiting | 30 |
| 2024-07-25 est. | P2 | DermBiont, Inc. | NCT06099080 A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN) | Dermatosis Papulosa Nigra | unknown | 10 |
| 2024-07-26 | P2 | Lepu Biopharma Co., Ltd. | NCT04868162 A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | completed | 70 |
| 2024-07-26 | P3 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) | Pulmonary Arterial Hypertension | completed | 173 |
| 2024-07-26 | P2 | ModernaTX, Inc. | NCT04917861 A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas | Zika Virus | completed | 808 |
| 2024-07-26 | P2 | StemCyte, Inc. | NCT05682560 Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome | Long COVID; Post-COVID Syndrome; Post COVID-19 Condition | completed | 30 |
| 2024-07-26 | P3 | PharmaEssentia Japan K.K. | NCT06002490 A Study to Evaluate P1101 in Japanese PV Patients | Polycythemia Vera (PV) | completed | 21 |
| 2024-07-27 | P2 | KinoPharma Inc. | NCT05896215 OM202JP Clinical Study of KNP2002 | Common Wart | completed | 159 |
| 2024-07-29 | P1/P2 | Dizal Pharmaceuticals | NCT03974022 Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | Non-Small Cell Lung Cancer | active not recruiting | 315 |
| 2024-07-29 | P3 | Hoffmann-La Roche | NCT05091567 A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Smal | Small-Cell Lung Cancer | active not recruiting | 660 |
| 2024-07-29 | P3 | Dompé Farmaceutici S.p.A | NCT05254990 Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia | Infectious Pneumonia; Severe COVID-19 | terminated | 414 |
| 2024-07-29 | P2 | AstraZeneca AZN | NCT05941897 A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cance | Advanced or Metastatic NSCLC | active not recruiting | 39 |
| 2024-07-29 | P3 | Janssen Research & Development, LLC | NCT06095115 A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | active not recruiting | 684 |
| 2024-07-29 | P2 | Bayer | NCT06195930 A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction | Chronic Heart Failure With Reduced Ejection Fraction | completed | 106 |
| 2024-07-29 | P3 | GlaxoSmithKline | NCT06389487 A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respi | Respiratory Syncytial Virus Infections | completed | 1459 |
| 2024-07-30 est. | P2 | Stemedica Cell Technologies, Inc. | NCT02833792 Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease | Alzheimer Dementia | unknown | 40 |
| 2024-07-30 est. | P3 | Techfields Pharma Co. Ltd | NCT03110523 A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar Spine | Osteoarthritis of the Lumbar Spine; Pain, Back | withdrawn | |
| 2024-07-30 est. | P2 | Kuros Biosurgery AG | NCT04294004 KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion | Degenerative Disc Disease; Spinal Fusion | unknown | 50 |
| 2024-07-30 | P2 | Provention Bio, a Sanofi Company | NCT04424927 PRV-015 in Gluten-free Diet Non-responsive Celiac Disease | Celiac Disease | completed | 388 |
| 2024-07-30 | P1/P2 | Olema Oncology, Inc. OLMA | NCT04505826 A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer | completed | 153 |
| 2024-07-30 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT04964518 A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | AML, Adult | unknown | 24 |
| 2024-07-30 | P2 | SonALAsense, Inc. | NCT05123534 A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG | Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma | suspended | 15 |
| 2024-07-30 est. | P3 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT05234684 A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma | Diffuse Large B Cell Lymphoma (DLBCL) | unknown | 150 |
| 2024-07-30 | P3 | Eli Lilly and Company LLY | NCT05260021 A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Bas | Type2 Diabetes; Diabetes Mellitus; Diabetes Mellitus, Type 2; T2D; T2DM (Type 2 Diabetes Mellitus); | completed | 99 |
| 2024-07-30 | P3 | GlaxoSmithKline | NCT05274750 Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps | Nasal Polyps | completed | 276 |
| 2024-07-30 est. | P1/P2 | BioNova Pharmaceuticals (Shanghai) LTD. | NCT05365100 A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL | CLL/SLL; NHL | withdrawn | |
| 2024-07-30 | P2 | Priovant Therapeutics, Inc. | NCT05523765 A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis | Non-infectious Intermediate Uveitis; Non-infectious Posterior Uveitis; Non-infectious Pan Uveitis | completed | 26 |
| 2024-07-30 | P3 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT05707832 A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus | Invasive Candidiasis; Invasive Aspergillosis | completed | 31 |
| 2024-07-30 | P3 | PainReform LTD | NCT05773846 A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical Pain | Bunion | completed | 428 |
| 2024-07-31 est. | P2/P3 | RemeGen Co., Ltd. | NCT03500380 A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | Breast Neoplasms; Breast Diseases; Capecitabine; HER2-positive Breast Cancer; HER2 Positive Breast C | unknown | 301 |
| 2024-07-31 | P1/P2 | Karyopharm Therapeutics Inc KPTIQ | NCT04256707 Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and | Non-Small Cell Lung Carcinoma (NSCLC); Colorectal Cancer (CRC); Other Solid Tumors | completed | 80 |
| 2024-07-31 | P2 | Seagen, a wholly owned subsidiary of Pfizer | NCT04430738 Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | Colorectal Carcinoma; Gastric Adenocarcinoma; GEJ Adenocarcinoma; Esophageal Adenocarcinoma; Cholang | active not recruiting | 40 |
| 2024-07-31 | P2 | Humanetics Corporation | NCT04482595 BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients | COVID-19; Long COVID; Pulmonary Fibrosis; Post-acute Respiratory Complications of COVID-19 | unknown | 50 |
| 2024-07-31 | P2 | AEON Biopharma, Inc. AEON | NCT05016661 Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention | Migraine | terminated | 466 |
| 2024-07-31 | P2 | Haihe Biopharma Co., Ltd. | NCT05043922 A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma | Ovarian Cancer; Recurrent Cancer | active not recruiting | 93 |
| 2024-07-31 | P3 | Enimmune Corporation | NCT05099029 A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children | Enterovirus Infections | completed | 3982 |
| 2024-07-31 est. | P2 | Genentech, Inc. | NCT05129423 A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | withdrawn | |
| 2024-07-31 | P1/P2 | TriSalus Life Sciences, Inc. TLSI | NCT05220722 Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma | terminated | 23 |
| 2024-07-31 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05300269 SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | Locally Advanced Rectal Cancer | unknown | 73 |
| 2024-07-31 | P2 | Hutchison Medipharma Limited | NCT05509699 Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer | Extensive-Stage Small Cell Lung Cancer | completed | 21 |
| 2024-07-31 | P3 | Acrotech Biopharma Inc. | NCT05571943 A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis | Atopic Dermatitis | completed | 542 |
| 2024-07-31 est. | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05715840 Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Met | Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) | unknown | 368 |
| 2024-07-31 est. | P2 | Hansoh BioMedical R&D Company | NCT06077331 A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis | Psoriasis | unknown | 120 |
| 2024-07-31 | P2 | Valneva Austria GmbH | NCT06106581 A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years | Chikungunya Virus Infection | completed | 304 |
| 2024-07-31 | P2 | Escient Pharmaceuticals, Inc | NCT06144424 Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermati | Atopic Dermatitis | completed | 32 |
| 2024-07-31 est. | P3 | WestVac Biopharma Co., Ltd. | NCT06175494 A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 | COVID-19 | unknown | 4800 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.